Inventi Impact: Ophthalmology

Inventi:hotm/22802/17

Efficacy and Tolerability of Travoprost 0.004%/Timolol 0.5% Fixed-Dose Combination for the\nTreatment of Primary Open-Angle Glaucoma or Ocular Hypertension Inadequately Controlled with\nBeta-Blocker Monotherapy

Objective. To evaluate the efficacy and tolerability of travoprost 0.004%/timolol 0.5% fixed-dose combination (TTFC) in patients\nwith open-angle glaucoma (OAG) or ocular hypertension (OHT) inadequately controlled on beta-blocker monotherapy. Methods.\nIn this phase IV, open-label study, 156 patients on beta-blocker monotherapy with mean intraocular pressure (IOP) between 18\nand 32mmHg were randomized (no washout period) to receive TTFC for 8 weeks (TTFC group) or to continue beta-blocker\nmonotherapy for 4 weeks followed by TTFC for the remaining 4 weeks (beta-blocker group). Results. The mean IOP (Ã?±standard\ndeviation) at baseline in the TTFC and beta-blocker groups was 22.5 Ã?± 2.5mmHg and 22.2 Ã?± 2.3mmHg, respectively, and at weeks\n4 and 8, was 16.7 Ã?± 3.1mmHg and 16.1 Ã?± 3.1mmHg, respectively, in TTFC group and 21.1 Ã?± 3.1mmHg and 16.1 Ã?± 2.8mmHg,\nrespectively, in the beta-blocker group. There was a significant least squares mean difference between TTFC and beta-blocker in 8\na.m. IOP at week 4 (âË?â??4.6mmHg; one-sided 95% confidence interval [âË?â??inf, âË?â??3.9];